

LIMITED TARIFF BENEFIT DISCLOSURE STATEMENT

Provide a signed hard copy to the Clerk of the Senate Committee on Finance located at 219 Dirksen SOB and a PDF version sent via email to mtb2009@finance-dem.senate.gov not later than five business days after the date of introduction of the bill.

Please be aware that this form will be made available to the public, media, and any other interested parties.

Part I. This form is being submitted for S. 2043, which I introduced in the Senate on October 29, 2009. If the bill referenced above is a modification of a previously introduced bill to reflect technical changes, please indicate the previous bill number here: S. N/A.

Part II. Please indicate the type of disclosure below: (Please check one only)
 The bill referenced in Part I is reasonably anticipated to benefit 10 or fewer individuals or entities, and as such constitutes a Limited Tariff Benefit. (Complete Part III)
 The bill referenced in Part I is reasonably anticipated to benefit more than 10 individuals or entities, and as such does not constitute a Limited Tariff Benefit.

Part III. Provide the information below in subparts A, B, and C if the bill referenced above is a Limited Tariff Benefit.

A. Anticipated Beneficiaries:


- Borregaard North America
- Davos Chemical

B. Purpose of the Limited Tariff Benefit:

To suspend the tariff for 3-amino-1,2-propanediol.

C. Financial Benefit Certification

I hereby certify that neither I nor my immediate family has a financial interest in the above described limited tariff benefit.



(Member Signature)

November 4, 2009

Date

Robert Menendez

(Print Member name)